Aventis, NPIL modify marketing pact
By Nisha Das | 20 Oct 2001
Mumbai: Aventis Pharma and Nicholas Piramal India (NPIL) have agreed to modify the existing co-marketing arrangement for the anti-diabetic molecule, glimepiride.
Aventis Pharma had launched glimepiride under the brand name Amaryl in May 1999. Subsequently, it entered into a co-marketing agreement with NPIL, which launched the same product under the name Glimer in December 1999.
Under the new agreement, NPIL and Aventis Pharma have converted the co-marketing agreement into a trademark-use agreement. Besides, Aventis will neither supply the active ingredient nor manufacture Glimer tablets for NPIL.
NPIL, however, will pay royalties to Aventis for the use of Glimer trademark to market glimepiride-based formulations, sourced and manufactured independently by it. This was necessitated to reflect the true market conditions in the wake of the low price competition and aggressive sales promotion. The new agreement also ensures stronger penetration of glimepiride with fair returns for both the parties.
Aventis Pharma will continue to market glimepiride under the brand name Amaryl, and NPIL will market its glimepiride formulations under the brand name Glimer.
